

ANRS EP 47 VISCONTI - VISCONTI cohort : International-Viro-Immunologic Sustained CONTROL after Treatment Interruption

Head :Saez-Cirion Asier

Last update : 10/25/2017 | Version : 3 | ID : 8455

General	
Identification	
Detailed name	VISCONTI cohort : International-Viro-Immunologic Sustained CONTROL after Treatment Interruption
Sign or acronym	ANRS EP 47 VISCONTI
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL approval
General Aspects	
Medical area	Immunology Infectious diseases
Health determinants	Iatrogenic Medicine
Keywords	primary infection, HIV treatment, functional remission, genetic characteristics, seropositivity, immune system, HIV
Scientific investigator(s) (Contact)	
Name of the director	Saez-Cirion
Surname	Asier
Address	25-28 RUE DU DOCTEUR ROUX 75015 PARIS
Email	asier.saez-cirion@pasteur.fr
Organization	ANRS - Institut
Collaborations	
Participation in projects, networks and consortia	Yes

Funding	
Funding status	Public
Details	ANRS
Governance of the database	
Sponsor(s) or organisation(s) responsible	ANRS - AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES
Organisation status	Public
Presence of scientific or steering committees	Yes
Additional contact	
Name of the contact	Hocqueloux
Surname	Laurent
Email	laurent.hocqueloux@chr-orleans.fr
Organization	CENTRE HOSPITALIER RÉGIONAL D'ORLÉANS
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Database objective	
Main objective	I-VISCONTI is a multicenter, multidisciplinary (clinicians, virologists, immunologists and epidemiologists) pathophysiologic study designed to explore the virological and immunological mechanisms responsible for sustained control of HIV-1 infection after ART interruption in adults or children who started treatment very early in the primary infection or during the chronic phase. I-VISCONTI also aims to identify markers that could

be used to identify patients who could reasonably interrupt their antiretroviral treatment.

Inclusion criteria	<p>Patients infected with HIV-1 and not co-infected with HIV-2</p> <ul style="list-style-type: none">- Whatever is the age at the time of HIV-1-infection- Plasma HIV RNA > 2000 copies/mL before initiation of antiretroviral therapy- Treatment started during the primary infection (as defined by symptoms associated with seroconversion, as confirmed by a first negative ELISA and/or an incomplete P24-positive Western blot), at the time of delivery for children or during the chronic phase of infection, and maintained for at least 12 months in both cases.- Control of viral load after antiretroviral treatment interruption: patients must have at least two available viral load assays after stopping antiretroviral therapy. All viral loads must be <400 copies/mL for 12 months or more after stopping antiretroviral therapy, with the possible exception of one blip (one viral load above 400 copies/mL between two viral loads <400 copies/mL at least one month apart from the blip; in this case at least three viral load assays will be required). The last plasma viral load value at the time of inclusion must always be <400 copies/mL
Population type	
Age	<p>Early childhood (2 to 5 years)</p> <p>Childhood (6 to 13 years)</p> <p>Adolescence (13 to 18 years)</p> <p>Adulthood (19 to 24 years)</p> <p>Adulthood (25 to 44 years)</p> <p>Adulthood (45 to 64 years)</p>
Population covered	Sick population
Pathology	Z21 - Asymptomatic human immunodeficiency virus [HIV] infection status
Gender	<p>Male</p> <p>Woman</p> <p>Other</p>
Geography area	International
Detail of the geography area	Metropolitan France.
Data collection	
Dates	

Date of first collection (YYYY or MM/YYYY)	2013
--	------

Size of the database

Size of the database (number of individuals)	< 500 individuals
--	-------------------

Details of the number of individuals	14 patients (primary infection).
--------------------------------------	----------------------------------

Data

Database activity	Current data collection
-------------------	-------------------------

Type of data collected	Clinical data Biological data
------------------------	----------------------------------

Clinical data (detail)	Direct physical measures Medical registration
------------------------	--

Biological data (detail)	Blood test.
--------------------------	-------------

Presence of a biobank	Yes
-----------------------	-----

Contents of biobank	Whole blood Plasma Blood cells isolated DNA
---------------------	--

Details of biobank content	Consult the scientist in charge.
----------------------------	----------------------------------

Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services
---------------------------	--

Care consumption (detail)	Hospitalization Medical/paramedical consultation Medicines consumption
---------------------------	--

Procedures

Participant monitoring	Yes
------------------------	-----

Details on monitoring of participants	7.5 years.
---------------------------------------	------------

Links to administrative sources	No
---------------------------------	----

Promotion and access

Promotion

Link to the document

<http://www.ncbi.nlm.nih.gov/pubmed/?term=ANRS+AND+visconti>

Description

List of publications in Pubmed

Access

Terms of data access (charter for data provision, format of data, availability delay)

PLOS PATHOGENS publication.

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only